| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/16/2006 | US20060057107 Combination treatment for multiple sclerosis |
| 03/16/2006 | US20060057105 Methods of treating ocular inflammation and allergy |
| 03/16/2006 | US20060057104 Methods for stimulating tlr irf3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses |
| 03/16/2006 | US20060057103 A mutein of IL-15 at least one deletion or substitution in two positions of the amino acid sequence; transplant rejection, autoimmune diseases, inflammatory bowel disease, skin disorders, gatrointestinal disorders, vision defects; antiarthritic, anticarcinogenic, and antidiabetic agents |
| 03/16/2006 | US20060057099 Ph-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy |
| 03/16/2006 | US20060057088 Vaccine for hair removal |
| 03/16/2006 | DE102004035337A1 Varianten der Gruppe 1-Allergene aus Poaceae mit reduzierter Allergenität und erhaltener T-Zellreaktivität Variants of the group 1 allergens from Poaceae with reduced allergenicity and preserved T cell reactivity |
| 03/16/2006 | CA2582534A1 Flavivirus variants having phenotypic variation and immunogenic compositions thereof |
| 03/16/2006 | CA2579859A1 Decreasing potential iatrogenic risks associated with influenza vaccines |
| 03/16/2006 | CA2579802A1 Methods and compositions for measuring natriuretic peptides and uses thereof |
| 03/16/2006 | CA2579558A1 Cancer-testis antigens |
| 03/16/2006 | CA2579488A1 Glycosylceramide adjuvant for saccharide antigens |
| 03/16/2006 | CA2579353A1 Therapeutic strategy for treating autoimmune and degenerative diseases |
| 03/16/2006 | CA2579352A1 Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor |
| 03/16/2006 | CA2579170A1 Crystal structure of house dust mite allergen der p 1 |
| 03/16/2006 | CA2579102A1 Compositions and methods for the diagnosis and treatment of tumor |
| 03/16/2006 | CA2579030A1 Controlled and directed local delivery of anti-inflammatory compositions |
| 03/16/2006 | CA2578046A1 Aptamer medicinal chemistry |
| 03/16/2006 | CA2577823A1 Methods of using death receptor ligands and cd20 antibodies |
| 03/16/2006 | CA2577405A1 Anti-fc-gamma riib receptor antibody and uses therefor |
| 03/16/2006 | CA2575997A1 Carrier conjugates of gnrh-peptides |
| 03/15/2006 | EP1634956A1 Recombinant adeno-associated virus vector for treatment of alzheimer disease |
| 03/15/2006 | EP1634953A2 Platelet-activating factor acethylhydrolase |
| 03/15/2006 | EP1634951A1 Novel protein |
| 03/15/2006 | EP1634949A1 Method for generating activated T-cells and antigen-pulsed antigen-presenting cells |
| 03/15/2006 | EP1634892A2 Composition and methods for the diagnosis of tumours |
| 03/15/2006 | EP1633882A1 Diagnostics and therapeutics for diseases associated with puromycin-insensitive leucyl-specific aminopeptidase (pils) |
| 03/15/2006 | EP1633872A2 Novel human protease inhibitor-like proteins and polynucleotides encoding the same |
| 03/15/2006 | EP1633860A2 IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA |
| 03/15/2006 | EP1633853A2 Severe acute respiratory syndrome dna vaccine compositions and methods of use |
| 03/15/2006 | EP1633850A2 Ovr115 ANTIBODY COMPOSITION AND METHODS OF USE |
| 03/15/2006 | EP1633786A2 Methods of treating alzheimer s disease using antibodies directed against amyloid beta peptide and compositions thereof |
| 03/15/2006 | EP1633785A2 Human monoclonal antibodies against bacillusanthracis protective antigen |
| 03/15/2006 | EP1633784A2 Ovr110 antibody compositions and methods of use |
| 03/15/2006 | EP1633778A1 Poly-gamma-glutamic acid conjugates for eliciting immune responses directed against bacilli |
| 03/15/2006 | EP1633777A2 Chlamydia pneumoniae antigens |
| 03/15/2006 | EP1633776A1 MODIFIED i BORDETELLA /i ADENYLATE CYCLASE COMPRISING OR LACKING CD11b/CD18 INTERACTION DOMAIN AND USES THEREOF |
| 03/15/2006 | EP1633775A2 Antigenic peptides of sars coronavirus and uses thereof |
| 03/15/2006 | EP1633401A1 A pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha |
| 03/15/2006 | EP1633396A1 Cd20 binding molecules |
| 03/15/2006 | EP1633395A1 Functionally reconstituted viral membranes containing adjuvant |
| 03/15/2006 | EP1633387A2 Combinations of tumor-associated antigens for the treatment of various types of cancers |
| 03/15/2006 | EP1633372A2 Vaccines, immunotherapeutics and methods for using the same |
| 03/15/2006 | EP1633316A2 Antibodies that immunospecifically bind to trail receptors |
| 03/15/2006 | EP1633312A2 Influenza hemagglutinin and neuraminidase variants |
| 03/15/2006 | EP1633309A2 Method of inhibiting tumor growth with anti-tissue factor antibodies |
| 03/15/2006 | EP1633308A2 Hiv-1 envelope glycoproteins having unusual disulfide structure |
| 03/15/2006 | EP1633304A2 Vascular endothelial growth factor fusion constructs and uses thereof |
| 03/15/2006 | EP1633189A2 Truncated fragments of alpha-synuclein in lewy body disease |
| 03/15/2006 | EP1521595B1 Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase |
| 03/15/2006 | EP1417300B1 Process for the maturation of dentritic cells and a vaccine |
| 03/15/2006 | EP1370589B1 Rationally designed antibodies |
| 03/15/2006 | EP1294893B1 Modification of hepatitis b core antigen |
| 03/15/2006 | EP1233783B9 Hbv/hcv virus-like particle |
| 03/15/2006 | EP1162997B1 Staphylococcus antigen and vaccine |
| 03/15/2006 | EP1044022B1 Compositions and methods for targeted delivery of factors |
| 03/15/2006 | EP1035863B1 An over-expressing homologous antigen vaccine and a method of making the same |
| 03/15/2006 | EP1001810B1 Pharmaceutical composition with neurotrophic-like biological activity |
| 03/15/2006 | EP0784477B1 Immunotherapeutic stress protein-peptide complexes against cancer |
| 03/15/2006 | EP0733069B1 Purified primate ctla-8 antigens and related reagents |
| 03/15/2006 | EP0733064B1 Nucleic acids encoding a house dust mite allergen, (der p iii), and uses therefor |
| 03/15/2006 | CN1748143A Transgenic mice expressing human cd20 and/or cd16 |
| 03/15/2006 | CN1747971A Antibody ('11c7') anti nogo a and its pharmaceutical use |
| 03/15/2006 | CN1747970A Antigen/antibody or ligand/receptor glycosylated specificity exchangers |
| 03/15/2006 | CN1747969A Immunoglobulin variants and uses thereof |
| 03/15/2006 | CN1747745A Hpv-16 and -18 l1 vlp vaccine. |
| 03/15/2006 | CN1746298A Artificial recombinant H7 subinfluenza virus, preparation and use thereof |
| 03/15/2006 | CN1746183A Coronavirus (SARS-CoV)B-cell antigen determinate cluster with extensive cross immune activity |
| 03/15/2006 | CN1745849A Human bivalent purified hydrophobia vaccine and its preparation |
| 03/15/2006 | CN1745848A Chitin-sodium alginate packed pylorus helicobacterium protein microballs and their preparation |
| 03/15/2006 | CN1245512C Vaccines containing recombinant pilin against i cneisseria gonorrhoeae (or i cneisseria meningitidis) |
| 03/15/2006 | CN1245419C Polynucleotides and polypeptides BASB033 from neisseria meningitidis and their uses |
| 03/15/2006 | CN1245217C Novel vaccine preparation consisting of DNA vaccine and inactivated rabies virus vaccine |
| 03/15/2006 | CN1245213C Microcapsule meterial for durative releasing two factors for restraining new-born blood vessels and its preparing method |
| 03/14/2006 | US7012135 Genetic engineering; monoclonal antibody grafted to tumor necrosis factor |
| 03/14/2006 | US7012134 Dendritic enriched secreted lymphocyte activation molecule |
| 03/14/2006 | US7012133 Antibodies to C-C chemokine Receptor 3 Protein |
| 03/14/2006 | US7012100 Cell migration inhibiting compositions and methods and compositions for treating cancer |
| 03/14/2006 | US7011845 For therapy and prophylaxis of infection or tumor |
| 03/14/2006 | US7011836 Neisseria having mutations in genes which causes the bacterium to lack endotoxic lipopolysaccharides, used for inoculation; genetic engineering; knockouts |
| 03/14/2006 | US7011835 Targeted destruction of pests |
| 03/14/2006 | US7011834 Immunomodulating dimers |
| 03/14/2006 | US7011833 Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent |
| 03/14/2006 | US7011826 Control of acidosis |
| 03/14/2006 | CA2171317C Method for purifying egg yolk immunoglobulins |
| 03/09/2006 | WO2006026689A2 Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine |
| 03/09/2006 | WO2006026470A2 Hiv immunostimulatory compositions |
| 03/09/2006 | WO2006026394A2 Method of eliciting an immune response against hiv |
| 03/09/2006 | WO2006026172A2 Use of soluble cd26 as inhibitor of angiogenesis and inflammation |
| 03/09/2006 | WO2006025580A1 Anti-histone h1 monoclonal antibody and hybridoma capable of producing the same |
| 03/09/2006 | WO2006025345A1 Antihuman baff antibody |
| 03/09/2006 | WO2006024954A2 Domains and epitopes of meningococcal protein nmb1870 |
| 03/09/2006 | WO2006024946A2 Improvements relating to meningococcal outer membrane vesicles |
| 03/09/2006 | WO2006024543A1 Vaccine against severe accute respiratory syndrome causing coronavirus (sars-cov) |
| 03/09/2006 | WO2006024518A1 Combination therapy for immunostimulation |
| 03/09/2006 | WO2006024367A2 Use of nkg2d receptor/nkg2d ligand interaction blockers in the treatment of auto-immune diseases |
| 03/09/2006 | WO2006024240A2 Vaccine composition against hepatitis c virus |
| 03/09/2006 | WO2006024122A1 Immunogenic compositions |
| 03/09/2006 | WO2006004878A9 Attenuated herpes simplex virus type-2, vectors thereof and immunogenic compositions thereof |
| 03/09/2006 | WO2005118644A3 Binding molecules capable of neutralizing rabies virus and uses thereof |